<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2022-5007</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-5007</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Продолжительность максимального времени между кардиоциклами при фибрилляции  предсердий для оценки риска артериальных тромбоэмболических осложнений</article-title><trans-title-group xml:lang="en"><trans-title>Maximum time between cardiac cycles in atrial fibrillation for assessing the risk of arterial  thromboembolism</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4833-4563</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Германова</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Germanova</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ольга Андреевна Германова — кандидат медицинских наук, директор Международного научно-образовательного центра кардиоваскулярной патологии и кардиовизуализации, доцент кафед ры пропедевтической терапии.</p><p>Самара</p></bio><bio xml:lang="en"><p>Samara</p></bio><email xlink:type="simple">olga.germanova111@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0367-7776</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Германов</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Germanov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Андрей Владимирович Германов — кандидат медицинских наук, доцент кафедры пропедевтической терапии.</p><p>Самара</p></bio><bio xml:lang="en"><p>Samara</p></bio><email xlink:type="simple">andreygermanov189@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0387-8356</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щукин</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shchukin</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Юрий Владимирович Щукин — доктор медицинских наук, профессор, заслуженный работник высшей школы РФ, заведующий кафедрой пропедевтической терапии.</p><p>Самара</p></bio><bio xml:lang="en"><p>Samara</p></bio><email xlink:type="simple">samsmu_pt@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО Самарский государственный медицинский университет Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Samara State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>08</day><month>08</month><year>2022</year></pub-date><volume>27</volume><issue>7</issue><fpage>5007</fpage><lpage>5007</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Германова О.А., Германов А.В., Щукин Ю.В., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Германова О.А., Германов А.В., Щукин Ю.В.</copyright-holder><copyright-holder xml:lang="en">Germanova O.A., Germanov A.V., Shchukin Y.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/5007">https://russjcardiol.elpub.ru/jour/article/view/5007</self-uri><abstract><sec><title>Цель</title><p>Цель. Определить развитие тромбоэмболических осложнений при различных вариантах фибрилляции предсердий (ФП), отличающихся по максимальному времени между кардиоциклами.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследование вошли 80 пациентов с постоянной формой ФП, контрольная группа — 88 человек без ФП. Выполнялись исследования: эхокардиография, суточное мониторирование электрокардиограммы; ультразвуковое исследование брахиоцефальных артерий, ветвей аорты, артерий нижних конечностей; сфигмография общей сонной и задней артерии голени. По показаниям — коронарография, панцеребральная ангиография, компьютерная томография головного мозга. На основании анализа суточного мониторирования электрокардиограммы все пациенты основной группы были разделены на 2 подгруппы (А и Б) в зависимости от максимального времени между кардиоциклами при ФП: подгруппа А (42) — больные с максимальным временем между кардиоциклами до 1,5 сек, подгруппа Б (38) — ≥1,5 сек. Наблюдение проводилось в течение 1 года. Во время периода наблюдения проводился анализ развития артериальных тромбоэмболических событий.</p></sec><sec><title>Результаты</title><p>Результаты. По основным параметрам инструментальных, лабораторных методов исследования, а также по сопутствующей патологии пациенты были равнозначны. Однако при изучении отдаленных осложнений в течение 1 года мы наблюдали достоверно более частое развитие инсульта, транзиторной ишемической атаки, инфаркта миокарда и дистальных артериальных эмболий артерий нижних конечностей в подгруппе Б. При увеличении максимального времени между кардиоциклами при ФП происходило увеличение параметров гемодинамики артериальных сосудов как на проксимальных, так и на дистальных артериях. Аналогичная тенденция наблюдалась и при анализе параметров кинетики артерий.</p></sec><sec><title>Заключение</title><p>Заключение. При оценке риска артериальных тромбоэмболических осложнений важен не только сам факт наличия у пациента ФП, но и то, какие особенности она имеет. Прогностически наиболее неблагоприятной является ФП с максимальной продолжительностью времени между кардиоциклами ≥1,5 сек. Рост показателей внутриартериальной гемодинамики после длительной паузы между сокращением желудочков при ФП без внутрисердечного тромбоза может стать ключевым моментом в развитии осложнений на уже имеющихся атеросклеротических бляшках, приводя к нарушению их целостности, что может стать источником дистальных эмболических осложнений различных локализаций.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To assess the development of thromboembolic events in different types of atrial fibrillation (AF), which differ in the maximum time between cardiac cycles.</p></sec><sec><title>Material and methods</title><p>Material and methods. The main group included 80 patients with permanent AF, while the control one — 88 people without AF. The following investigations were performed: echocardiography, 24-hour electrocardiographic (ECG) monitoring; ultrasound of extracranial arteries, aortic branches, lower limb arteries; sphygmography of the common carotid and posterior tibial arteries. If required, coronary angiography, cerebral angiography, brain computed tomography were performed. According to 24-hour ECG monitoring, all patients of the main group were divided into 2 subgroups (A and B) depending on the maximum time between cardiac cycles in AF: subgroup A (n=42) — patients with a maximum time between cardiac cycles &lt;1,5 seconds, subgroup B (n=38) — ≥1,5. The followup period lasted 1 year. During the follow-up period, the development of arterial thromboembolic events was analyzed.</p></sec><sec><title>Results</title><p>Results. The patients were comparable in key paraclinical characteristics and comorbidity profile. One-year follow-up period revealed a significantly higher incidence of stroke, transient ischemic attack, myocardial infarction, and distal arterial embolism of lower limb arteries in subgroup B. With an increase in the maximum time between cardiac cycles in AF, an increase in hemodynamic parameters of arterial vessels occurred as both proximal and distal arteries. A similar trend was also observed in the analysis of arterial kinetic parameters.</p></sec><sec><title>Conclusion</title><p>Conclusion. Not only the fact of AF presence is important for assessing the risk of arterial thromboembolism, but also its features. The most unfavorable for prognosis is AF with a maximum time between cardiac cycles ≥1,5 seconds. An increase in intra-arterial hemodynamic parameters after a long pause between ventricular contractions in AF without intracardiac thrombosis can become a key factor in the development of complications with existing plaques, which can become a source of distal embolism.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>фибрилляция предсердий</kwd><kwd>тромбоэмболические осложнения</kwd><kwd>гемодинамика артерий</kwd></kwd-group><kwd-group xml:lang="en"><kwd>atrial fibrillation</kwd><kwd>thromboembolic events</kwd><kwd>arterial hemodynamics</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021. Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021;52(7):e364-e467. doi:10.1161/STR.0000000000000375. Erratum in: Stroke. 2021;52(7):e483-e484.</mixed-citation><mixed-citation xml:lang="en">Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021 Jul;52(7):e364-e467. doi: 10.1161/STR.0000000000000375. Epub 2021 May 24. Erratum in: Stroke. 2021 Jul;52(7):e483-e484. PMID: 34024117.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Virani SS, Alonso A, Benjamin EJ, et al.; on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2020 update: a report from the American Heart Association. Circulation. 2020;141:e139-e596. doi:10.1161/CIR.0000000000000757.</mixed-citation><mixed-citation xml:lang="en">Virani SS, Alonso A, Benjamin EJ, et al; on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2020 update: a report from the American Heart Association. Circulation. 2020;141:e139–e596. doi: 10.1161/CIR.0000000000000757</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Bennett DA, Krishnamurthi RV, Barker-Collo S, et al.; Global Burden of Diseases, Injuries, and Risk Factors 2010 Study Stroke Expert Group. The global burden of ischemic stroke: findings of the GBD 2010 study. Glob Heart. 2014;9:107-12. doi:10.1016/j.gheart. 2014.01.001.</mixed-citation><mixed-citation xml:lang="en">Bennett DA, Krishnamurthi RV, Barker-Collo S, et al.; Global Burden of Diseases, Injuries, and Risk Factors 2010 Study Stroke Expert Group. The global burden of ischemic stroke: findings of the GBD 2010 study. Glob Heart. 2014; 9:107–112. doi: 10.1016/j.gheart.2014.01.001</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Béjot Y, Bailly H, Durier J, Giroud M. Epidemiology of stroke in Europe and trends for the 21st century. Presse Med. 2016; 45(12 pt 2):e391-e398. doi:10.1016/j.lpm.2016.10.003.</mixed-citation><mixed-citation xml:lang="en">Béjot Y, Bailly H, Durier J, Giroud M. Epidemiology of stroke in Europe and trends for the 21st century. Presse Med. 2016; 45(12 pt 2):e391–e398. doi: 10.1016/j.lpm.2016.10.003</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442. doi:10.1371/journal.pmed.0030442.</mixed-citation><mixed-citation xml:lang="en">Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030.PLoS Med. 2006; 3:e442. doi: 10.1371/journal.pmed.0030442</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Gardener H, Sacco RL, Rundek T, et al. Race and ethnic disparities in stroke incidence in the Northern Manhattan Study. Stroke. 2020;51:1064-9. doi:10.1161/STROKEAHA.119.028806.</mixed-citation><mixed-citation xml:lang="en">Gardener H, Sacco RL, Rundek T, Battistella V, Cheung YK, Elkind MSV. Race and ethnic disparities in stroke incidence in the Northern Manhattan Study. Stroke. 2020;51:1064–1069. doi: 10.1161/STROKEAHA.119.028806</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Hart RG, Diener HC, Coutts SB, et al.; Cryptogenic Stroke/ESUS International Working Group. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13:429-38. doi:10.1016/S1474-4422(13)70310-7.</mixed-citation><mixed-citation xml:lang="en">Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, et al; Cryptogenic Stroke/ESUS International Working Group. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13:429–438. doi: 10.1016/S1474-4422(13)70310-7</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Benjamin EJ, Muntner P, Alonso A, et al., American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics — 2019 update: a report from the American Heart Association. Circulation 2019;139:e56-e528.</mixed-citation><mixed-citation xml:lang="en">Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al., American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2019 update: a report from the American Heart Association. Circulation 2019;139:e56–e528.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Allan V, Honarbakhsh S, Casas JP, et al. Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants. Thromb Haemost. 2017;117:837-50.</mixed-citation><mixed-citation xml:lang="en">Allan V, Honarbakhsh S, Casas JP et al. Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants. Thromb Haemost. 2017;117:837–850.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Chao TF, Liu CJ, Tuan TC, et al. Lifetime risks, projected numbers, and adverse outcomes in Asian patients with atrial fibrillation: a report from the Taiwan Nationwide AF Cohort Study. Chest. 2018;153:453-66.</mixed-citation><mixed-citation xml:lang="en">Chao TF, Liu CJ, Tuan TC et al. Lifetime risks, projected numbers, and adverse outcomes in Asian patients with atrial fibrillation: a report from the Taiwan Nationwide AF Cohort Study. Chest. 2018;153:453–466.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Delgado V, Biase LDi, Leung M, et al. Structure and function of the left atrium and left atrial appendage: AF and stroke implications. J Am Coll Cardiol. 2017;70:3157-72.</mixed-citation><mixed-citation xml:lang="en">Delgado V, Biase LDi, Leung M et al. Structure and function of the left atrium and left atrial appendage: AF and stroke implications. J Am Coll Cardiol. 2017;70:3157–3172.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Chao TF, Lip GY, Liu CJ, et al. Validation of a modified CHA2DS2-VASc score for stroke risk stratification in Asian patients with atrial fibrillation: a nationwide cohort study. Stroke. 2016;47:2462-9.</mixed-citation><mixed-citation xml:lang="en">Chao TF, Lip GY, Liu CJ et al. Validation of a modified CHA2DS2-VASc score for stroke risk stratification in Asian patients with atrial fibrillation: a nationwide cohort study. Stroke. 2016;47: 2462–2469.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Curry SJ, Krist AH, Owens DK, et al. Screening for atrial fibrillation with electrocardiography: US preventive services task force recommendation statement. JAMA. 2018;320:478-84.</mixed-citation><mixed-citation xml:lang="en">Curry SJ, Krist AH, Owens DK et al. Screening for atrial fibrillation with electrocardiography: US preventive services task force recommendation statement. JAMA. 2018;320:478–484.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Germanova O, Galati G, Germanov A, Stefanidis A. Atrial fibrillation: a new independent risk factor for thromboembolic events — hemodynamics and vascular consequence of long ventricular pauses. Minerva Cardiology and Angiology. 2022. doi:10.23736/S27245683.22.06000-8.</mixed-citation><mixed-citation xml:lang="en">Germanova O, Galati G, Germanov A, Stefanidis A. Atrial fibrillation: a new independent risk factor for thromboembolic events - hemodynamics and vascular consequence of long ventricular pauses. Minerva Cardiology and Angiology. 2022. doi: 10.23736/S2724-5683.22.06000-8</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Germanova OA, Germanov AV, Shchukin YuV. Device for modeling of intra-arterial circulation: application in experimental cardiology. European Heart Journal. 2021;42:1.</mixed-citation><mixed-citation xml:lang="en">Germanova OA, Germanov AV, Shchukin YuV. Device for modeling of intra-arterial circulation: application in experimental cardiology. European Heart Journal. 2021;42:1.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
